{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:21:46Z","timestamp":1762507306644},"reference-count":24,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2018]]},"DOI":"10.1536\/ihj.17-099","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T17:23:19Z","timestamp":1516987399000},"page":"87-93","source":"Crossref","is-referenced-by-count":15,"title":["Tolvaptan Improves Prognosis in Responders with Acute Decompensated Heart Failure by Reducing the Dose of Loop Diuretics"],"prefix":"10.1536","volume":"59","author":[{"given":"Makiko","family":"Nakamura","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osahiko","family":"Sunagawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","first-page":"1319","volume":"297","year":"2007","unstructured":"1. Konstam MA, Gheorghiade M, Burnett JC Jr, <i>et al<\/i>. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.","journal-title":"JAMA The Journal of the American Medical Association","ISSN":"http:\/\/id.crossref.org\/issn\/0098-7484","issn-type":"print"},{"key":"2","unstructured":"2. Imamura T, Kinugawa K, Shiga T, <i>et al<\/i>. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404."},{"key":"3","unstructured":"3. Imamura T, Kinugawa K, Minatsuki S, <i>et al<\/i>. Tolvaptan can improve clinical course in responders validation analysis for the definition of responsiveness by urine volume. Int Heart J 2013; 54: 377-81."},{"key":"4","unstructured":"4. Felker GM, Lee KL, Bull DA, <i>et al<\/i>. diuretic strategies in patients with acute decompensated heart failure. N Eng J Med 2011; 364: 797-805."},{"key":"5","unstructured":"5. Felker GM, O&apos;Connor CM, Braunwald E; Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2009; 2: 56-62."},{"key":"6","unstructured":"6. Imamura T, Kinugawa K, Fujino T, <i>et al<\/i>. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78: 2240-9."},{"key":"7","unstructured":"7. Matsue Y, Suzuki M, Torii S, <i>et al<\/i>. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 63: 169-74."},{"key":"8","unstructured":"8. Matsue Y, Suzuki M, Seya M, <i>et al<\/i>. Clinical effectiveness of tolvaptan in patients with acute heart failure and renal dysfunction. J Cardiac Fail 2016; 22: 423-32."},{"key":"9","unstructured":"9. Butler J, Forman DE, Abraham WT, <i>et al<\/i>. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004; 147: 331-8."},{"key":"10","unstructured":"10. Cowie MR, Komajda M, Murray-Thomas T, <i>et al<\/i>. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006; 27: 1216-22."},{"key":"11","unstructured":"11. Nohria A, Hasselblad V, Stebbins A, <i>et al<\/i>. Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008; 51: 1268-74."},{"key":"12","unstructured":"12. Klein L, Massie BM, Leimberger JD, <i>et al<\/i>. OPTIME-CHF Investigators. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008; 1: 25-33."},{"key":"13","unstructured":"13. Blair JE, Burnett J, Konstam MA, <i>et al<\/i>. Prognostic value and changes in renal function in patients admitted with acute heart failure - results from the EVEREST program. Eur J Heart Fail 2008; 7: 204. (Abstract)."},{"key":"14","unstructured":"14. Metra M, Nodari S, Parrinello G, <i>et al<\/i>. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008; 10: 188-95."},{"key":"15","unstructured":"15. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53: 557-73."},{"key":"16","unstructured":"16. Heywood JT, Fonarow GC, Costanzo MR, <i>et al<\/i>. For The ADHERE Scientific Advisory Committee and Investigators. High Prevalence of Renal Dysfunction and Its Impact on Outcome in 118,465 Patients Hospitalized With Acute Decompensated Heart Failure: a Report From the ADHERE Database. J Cardiac Fail 2007; 13: 422-30."},{"key":"17","unstructured":"17. Hasselblad V, Stough WG, Shah MR, <i>et al<\/i>. relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007; 9: 1064-9."},{"key":"18","unstructured":"18. Udelson JE, Orlandi C, Ouyang J, <i>et al<\/i>. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-5."},{"key":"19","unstructured":"19. Matsuzaki M, Hori M, Izumi T, <i>et al<\/i>. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25: S33-45."},{"key":"20","unstructured":"20. Schrier RW, Gross P, Gheorghiade M, <i>et al<\/i>. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-112."},{"key":"21","unstructured":"21. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-61."},{"key":"22","unstructured":"22. Shirakabe A, Hata N, Yamamoto M, <i>et al<\/i>. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 2014; 78: 911-21."},{"key":"23","unstructured":"23. Hanatani A, Shibata A, Kitada R, <i>et al<\/i>. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels 2017; 32: 287-94."},{"key":"24","unstructured":"24. Kadota M, Ise T, Yagi S, <i>et al<\/i>. Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin-angiotensin-aldosterone system and arginine vasopressin. Int Heart J 2016; 57: 461-5."}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/1\/59_17-099\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T23:51:13Z","timestamp":1517010673000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/59\/1\/59_17-099\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.17-099","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018]]}}}